Alec Saitman (Presenter)
Providence Regional Laboratories
Bio: Dr. Saitman received his Ph.D. in Organic Chemistry at the University of California, San Diego where he focused his research on the total synthesis of marine natural products. He completed his fellowship training in Clinical Chemistry and Toxicology in the Department of Pathology at the University of California, San Diego under the guidance of Dr. Robert Fitzgerald. Dr. Saitman is double boarded by the American Board of Clinical Chemistry in Clinical Chemistry and Clinical Toxicology. He is Currently the Director of Toxicology and Special Chemistry at Providence Regional Laboratories in Portland Oregon.
Authorship: Alec Saitman
Providence Regional Laboratories, Portland Oregon
| Short Abstract This session talk is designed for the absolute beginner with little to no previous experience with clinical mass spectrometry. Mass spectrometry is a broad scientific area and this section will focus on one of the most relevant clinical applications, the use of liquid chromatography tandem mass spectrometry in the clinical laboratory. |
Long Abstract
This session talk is designed for the absolute beginner with little to no previous experience with clinical mass spectrometry. Mass spectrometry is a broad scientific area and this section will focus on one of the most relevant clinical applications, the use of liquid chromatography tandem mass spectrometry in the clinical laboratory. This session will provide, 1) a brief overview of liquid chromatography and electrospray ionization 2) a brief overview of how a tandem mass spectrometer detects and counts molecules, 3) a description of the use of internal standards (IS) and why they are used, and finally 4) a description of how calibration curves can generate quantitative results from unknown patient samples. This session will emphasize why more and more clinical laboratories are turning to mass spectrometry as a “gold standard” for quantitative and confirmatory testing of small molecules in patient samples and highlight how the use of mass spectrometry is superior to alternative clinical methods.
References & Acknowledgements:
| Description | Y/N | Source |
| Grants | no | |
| Salary | no | |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |